Serina Therapeutics

Serina Therapeutics is advancing a proprietary polymer platform, POZylation, to 'turn good molecules into great medicines' by extending drug half-life, reducing dosing frequency, and improving patient convenience. The company's near-term value driver is SER-252, a long-acting formulation of apomorphine for advanced Parkinson's disease, which has entered a Phase 1b registrational trial under a 505(b)(2) pathway. Backed by decades of polymer research and strategic partnerships, Serina employs a capital-efficient development model focused on enhancing known molecules to address significant unmet needs in CNS and beyond.

The POZ Platform™ (POZylation) is a proprietary, non-immunogenic polymer conjugation technology designed to covalently attach to small molecule drugs, enabling controlled, sustained release to extend half-life, reduce dosing frequency, and improve tolerability.

In Parkinson's, SER-252 competes against apomorphine infusion pumps and other advanced therapies, differentiating on convenience. In drug delivery, it competes with PEGylation and other polymer technologies, claiming superiority via POZ's non-immunogenic profile. It is one of 103 public drug delivery companies.